We are live on
!
Find out more
CFO
Callan Family Office Portfolio holdings
AUM
$4.41B
1-Year Est. Return
26.21%
This Fund
S&P 500
This Quarter
Est. Return
+12.78%
1 Year Est. Return
+26.21%
3 Year Est. Return
+68.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.17B
AUM Growth
+$1.84B
(+138%)
Cap. Flow
+$1.59B
Cap. Flow
% of AUM
50.05%
Top 10 Holdings %
Top 10 Hldgs %
25.88%
Holding
941
New
398
Increased
483
Reduced
23
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$74.8M |
| 2 |
NVIDIA
NVDA
|
+$66.1M |
| 3 |
Apple
AAPL
|
+$49.9M |
| 4 |
Amazon
AMZN
|
+$46.4M |
| 5 |
Meta Platforms (Facebook)
META
|
+$31.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
DFS
Discover Financial Services
DFS
|
+$2.79M |
| 2 |
iShares Russell 1000 Value ETF
IWD
|
+$1.79M |
| 3 |
iShares Core S&P Mid-Cap ETF
IJH
|
+$1.74M |
| 4 |
iShares S&P 500 Value ETF
IVE
|
+$1.28M |
| 5 |
Vanguard Morningstar Total Stock Market ETF
VTI
|
+$1.26M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 23.33% |
| 2 | Financials | 14.81% |
| 3 | Healthcare | 9.6% |
| 4 | Industrials | 7.93% |
| 5 | Communication Services | 7.86% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
TE
926
T1 Energy
TE
$1.63B
| $12.7K | ﹤0.01% |
+10,288
| New | +$12.5K |
|
927
Pacific Biosciences
PACB
$370M
| $12.4K | ﹤0.01% |
+10,024
| New | +$11.6K |
|
928
Sutro Biopharma
STRO
$421M
| $11.5K | ﹤0.01% |
+1,618
| New | +$13.2K |
|
|
NOTE
929
DELISTED
FiscalNote
NOTE
| $10.8K | ﹤0.01% |
+1,677
| New | +$12.6K |
|
930
ALX Oncology
ALXO
$290M
| $8.21K | ﹤0.01% |
+19,778
| New | +$9.98K |
|
931
Opendoor
OPEN
$3.38B
| $6.3K | ﹤0.01% |
+12,217
| New | +$8.83K |
|
932
Cabaletta Bio
CABA
$455M
| – | – |
-41,599
| Closed | -$57.6K |
|
933
Criteo S.A. Ordinary Shares
CRTO
$923M
| – | – |
-7,347
| Closed | -$260K |
|
|
DFS
934
DELISTED
Discover Financial Services
DFS
| – | – |
-16,316
| Closed | -$2.79M |
|
935
Fate Therapeutics
FATE
$326M
| – | – |
-82,024
| Closed | -$64.8K |
|
936
Hudbay
HBM
$12.3B
| – | – |
-53,883
| Closed | -$409K |
|
937
iShares Russell 2000 Growth ETF
IWO
$15B
| – | – |
-843
| Closed | -$215K |
|
|
RAPT
938
DELISTED
RAPT Therapeutics
RAPT
| – | – |
-11,166
| Closed | -$109K |
|
|
TGB
939
Trekor Metals
TGB
$3.05B
| – | – |
-54,528
| Closed | -$122K |
|
940
Vanguard Morningstar Small-Cap ETF
VB
$82.7B
| – | – |
-1,247
| Closed | -$277K |
|
|
X
941
DELISTED
US Steel
X
| – | – |
-6,165
| Closed | -$261K |
|
Similar funds
FIS
CAU
EQF
SFM
EC
IC
GIBU
Callan Family Office's Q2 2025 Portfolio in Review
As of Q2 2025, Callan Family Office held 941 positions worth $3.17B, up 138% from $1.33B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
Callan Family Office deployed $1.59B of net new capital in Q2 2025, opening 398 new positions and adding to 483 existing holdings. Its largest new stake was Fortive: 72,724 shares worth $3.79M.
By sector, the portfolio is most concentrated in Technology at 23% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
On the sell side, the largest reduction was iShares Russell 1000 Value ETF, an estimated $1.79M trimmed.
- Callan Family Office's largest Q2 2025 buy was Fortive: 72,724 shares worth $3.79M.
- Callan Family Office added most to Microsoft in Q2 2025, an estimated $74.8M increase.
- Callan Family Office's biggest Q2 2025 reduction was iShares Russell 1000 Value ETF, cutting an estimated $1.79M.
- Callan Family Office fully exited Discover Financial Services in Q2 2025, selling an estimated $2.79M.
- Callan Family Office's ten largest holdings make up 26% of its $3.17B portfolio in Q2 2025.
- Callan Family Office opened 398 new positions and closed 10 in Q2 2025.
- Callan Family Office's portfolio value rose 138% quarter-over-quarter to $3.17B.
Based on Callan Family Office's 13F filing for Q2 2025, filed 24 Jul 2025.